Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat

Acta Oto-Laryngologica

Volumn 123, Issue 5, 2003, Pages 559-563

  Chae, Sung Won ^a   Kim, Seo Jin ^a   Kim, Jeung Lim ^a   Jung, Hak Hyun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Gene expression; Polymerase chain reaction; Rat; Vascular permeability

Indexed keywords

ENDOTOXIN; MESSENGER RNA; SODIUM CHLORIDE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; MIDDLE EAR MUCOSA; NONHUMAN; NUCLEOTIDE SEQUENCE; OTITIS MEDIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENDOTOXINS; GENE EXPRESSION REGULATION; MUCOUS MEMBRANE; OTITIS MEDIA WITH EFFUSION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0038236526     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480310001501     Document Type: Article

References (24)

1. Lim DJ, Birck H. Ultrastructural pathology of the middle ear mucosa in serous otitis media. Ann Otol Rhinol Laryngol 1971; 80: 838-53.
2. Nell MJ, Grote JJ. Structural changes in the rat middle ear mucosa due to endotoxin and eustachian tube obstruction. Eur Arch Otorhinolaryngol 1999; 256: 167-72.
3. Rhee CK, Park YS, Long SA, Jung TT, Davamony D. Effects of platelet activating factor on vascular permeability of the middle ear mucosa. Ann Otol Rhinol Laryngol 1997; 106: 604-7.
4. Goldie P, Jung TT, Hellstrom S. Arachidonic acid metabolites in experimental otitis media and effects of anti-inflammatory drugs. Ann Otol Rhinol Laryngol 1993; 102: 954-60.
5. Boisvert P, Wasserman SI, Schiff M, Ryan AF. Histamine-induced middle ear effusion and mucosal histopathology in the guinea pig. Ann Otol Rhinol Laryngol 1985; 94: 212-6.
6. Jung HH, Kim MW, Lee JH, et al. Expression of vascular endothelial growth factor in otitis media. Acta Otolaryngol (Stockh) 1999; 119: 801-8.
7. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-8.
8. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
9. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
10. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
11. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.
12. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors [Review]. FASEB J 1999; 13: 9-22.
13. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273: 31273-82.
14. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-46.
15. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-51.
16. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6.
17. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
18. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 and KDR: a reassessment using novel highly receptor-specific VEGF mutants. J Biol Chem 2001; 276: 3222-30.
19. Stacker SA, Vitali A, Caesar C, et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 1999; 274: 34884-92.
20. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
21. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
22. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979; 122: 166-74.
23. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995; 92: 3566-70.
24. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829-37.